Sorted By Test Name - Mayo Medical Laboratories

F_2
9121
F2IS
7805
been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such
clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as
investigational or for research. This laboratory is certified under the Clinical Laboratory Improvement
Amendment of 1988 (“CLIAâ€) as qualified to perform high complexity clinical testing.
Test Performed by: Univ of Colorado Hospital
Clinical Laboratory
12401 E. 17th Ave
Aurora, CO 80045
Coagulation Factor II Activity Assay, Plasma
Clinical Information: Factor II (prothrombin) is a vitamin K-dependent serine protease synthesized
in liver. It participates in the final common pathway of coagulation, as the substrate for the
prothrombinase enzyme complex. Prothrombin is the precursor of thrombin (IIa) which converts
fibrinogen to fibrin. Plasma biological half-life is about 3 days. Deficiency of factor II may cause
prolonged prothrombin time and activated partial thromboplastin time. Deficiency may result in a
bleeding diathesis.
Useful For: Diagnosing a congenital deficiency (rare) of coagulation factor II Evaluating acquired
deficiencies associated with liver disease or vitamin K deficiency, oral anticoagulant therapy, and
antibody-induced deficiencies (eg, in association with lupus-like anticoagulant) Determining warfarin
treatment stabilization in patients with nonspecific inhibitors (ie, lupus anticoagulant) Determining degree
of anticoagulation with warfarin to correlate with level of protein S Investigation of prolonged
prothrombin time or activated partial thromboplastin time
Interpretation: Liver disease, vitamin K deficiency, or warfarin anticoagulation can cause decreased
factor II activity. Homozygotes generally have levels of or =180 days postnatal.*
*See Pediatric Hemostasis References in Coagulation Studies in Special Instructions.
Clinical References: 1. Lancellotti S, De Cristofaro R: Congenital prothrombin deficiency. Semin
Thromb Hemost 2009 Jun;35(4):367-381 2. Peyvandi F, Bolton-Maggs PH, Batorova A, De Moerloose P:
Rare bleeding disorders. Haemophilia 2012 Jul;18 Suppl 4:148-153 3. Girolami A, Scandellari R, Scapin
M, Vettore S: Congenital bleeding disorders of the vitamin K-dependent clotting factors. Vitam Horm
2008;78:281-374 4. Brenner B, Kuperman AA, Watzka M, Oldenburg J: Vitamin K-dependent
coagulation factors deficiency. Semin Thromb Hemost 2009 Jun;35(4):439-446
Coagulation Factor II Inhibitor Screen, Plasma
Clinical Information: Coagulation factor inhibitors arise in patients who are congenitally deficient in
a specific factor in response to factor replacement therapy, or can occur spontaneously without known
cause or in response to a variety of medical conditions including the postpartum state, immunologic
disorders, certain antibiotic therapies, some malignancies, and old age. Inhibitors of factor VIII coagulant
activity are the most commonly occurring of the specific factor inhibitors.
Useful For: Detection and quantitation of inhibitor to factor II
Interpretation: Normally, there is no inhibitor, ie, negative. If the screening assays indicate the
presence of an inhibitor, it will be quantitated and reported in Bethesda (or equivalent) units.
Reference Values:
FACTOR II ACTIVITY ASSAY
Current as of January 4, 2013 7:15 pm CST 800-533-1710 or 507-266-5700 or MayoMedicalLaboratories.com Page 485